These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32703503)

  • 1. Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
    Wu Q; Wang W; Zhou P; Fu Y; Zhang Y; Shao YW; Jiang L
    Pathol Res Pract; 2020 Aug; 216(8):153043. PubMed ID: 32703503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses.
    Chen B; Zhang Y; Dai S; Zhou P; Luo W; Wang Z; Chen X; Cheng P; Zheng G; Ren J; Yang X; Li W
    Signal Transduct Target Ther; 2021 Jan; 6(1):6. PubMed ID: 33414372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
    Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
    Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
    Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
    Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
    Jain E; Sharma S; Aggarwal A; Bhardwaj N; Dewan A; Kumar A; Jain D; Bhattacharya M; Saurav GK; Kini L; Mohanty SK
    Pathol Res Pract; 2021 Dec; 228():153497. PubMed ID: 34053784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with
    Cho JH; Zhou W; Choi YL; Sun JM; Choi H; Kim TE; Dolled-Filhart M; Emancipator K; Rutkowski MA; Kim J
    Cancer Res Treat; 2018 Jan; 50(1):95-102. PubMed ID: 28301925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
    Yang CY; Lin MW; Chang YL; Wu CT
    Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
    Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.
    Lamberti G; Spurr LF; Li Y; Ricciuti B; Recondo G; Umeton R; Nishino M; Sholl LM; Meyerson ML; Cherniack AD; Awad MM
    Ann Oncol; 2020 Jun; 31(6):807-814. PubMed ID: 32171752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
    Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
    Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
    Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
    Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
    Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
    Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.